At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.

Please fill out the following form to access this resource:

First Name*
Last Name*
Email Address*
Phone Number*
City*
Country*
State*
Company/Institute*
CAPTCHA

Related Resources

View All Resources

Antibody Discovery

Brochure: Get to the Clinic First with Best-In-Class Antibody Therapeutics

Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.

Antibody Discovery

Webinar: Antibody Engineering & Therapeutics Digital Week 2019

Learn about accelerating target-to-lead antibody candidate selection with the Beacon platform in this Antibody Engineering & Therapeutics Digital Week 2019 webinar.

Antibody Discovery

Application Note: Rapid High-Resolution Screening of Plasma B Cells to Identify Antibody Lead Candidates

Explore case studies for the rapid discovery of antibodies against challenging targets.